Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Elizabeth Sturgill"'
Autor:
Yaping Wu, Brendan D. Curti, Zhaoyu Sun, William L. Redmond, Brady Bernard, Christopher B. Fountain, Peter G. Traber, Takashi Shimada, Yoshinobu Koguchi, Rom Leidner, Eliezer Zomer, Elizabeth Sturgill, George Morris, Venkatesh Rajamanickam, Noriko Iwamoto, Annah S Rolig, Ian Hilgart-Martiszus, J. Rex Horton, Shu Ching Chang, Harold Shlevin
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundPD-1/PD-L1 engagement and overexpression of galectin-3 (Gal-3) are critical mechanisms of tumor-induced immune suppression that contribute to immunotherapy resistance. We hypothesized that Gal-3 blockade with belapectin (GR-MD-02) plus anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a1c844347afeb00988b18adab8210ae
https://jitc.bmj.com/content/9/4/e002371.full
https://jitc.bmj.com/content/9/4/e002371.full
Autor:
Stefanie N. Linch, Harold Shlevin, Melissa J Kasiewicz, Annah S Rolig, William L. Redmond, Peter G. Traber, Elizabeth Sturgill, Zhaoyu Sun, Courtney Mick
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Treatment with an agonist anti-OX40 antibody (aOX40) boosts anti-tumor immunity by providing costimulation and driving effector T cell responses. However, tumor-induced immune suppression contributes significantly to poor response rates to aOX40 ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a581525ac509ed20d0123981b59a8b3
https://doi.org/10.1080/2162402x.2021.1892265
https://doi.org/10.1080/2162402x.2021.1892265